HILOmet PhyzioType System

The HILOmet PhyzioType System for drug safety and selection developed by the Genomas Laboratory of Personalized Health is a multi-gene DNA test combination that determines the innate drug metabolic capacity of the patient for use in personalizing drug treatments and diagnosing adverse drug reactions. The assays are non-invasive and require only a blood sample or buccal swab. Based on Genomas clinical studies and case reports, the HILOmet PhyzioType offers interpretative guidance to assess the functional status of a patient's drug metabolism in order to establish capabilities and deficiencies. The HILOmet PhyzioType System enables clinicians to select the drug with the least risk and superior efficacy based on data derived from the patient's own genome.

The effectiveness of several neuro-psychiatric and cardio-metabolic drugs and their potential therapeutic benefits and side effects are dependant on drug metabolism. For many drugs this metabolism is accomplished by the Cytochrome P450 (CYP450) enzyme system located in the liver. Variability in the CYP450 system, accumulated since prehistoric times, results in strikingly different drug levels, drug effectiveness and drug safety among individuals now treated with drugs where the recommended dose is designed to treat the  "average" person.  With DNA-guided medicine, these CYP450 variances can now be measured, so that drug selection and dosing are tailored to provide safe and effective therapy for individual patients.

The HILOmet Phyziotype® System offers clinicians the ability to personalize drug therapy and increase safety and compliance in the most challenging cases:

  • Patients experiencing drug intolerance, side effects, treatment resistance or therapeutic failure to medications
  • Patients treated with combinations of medications or medical devices
  • Children, adolescents, the elderly and the infirm
  • Patients hospitalized or with multiple medical conditions

Patients intolerant to neuro-psychiatric and cardio-metabolic medicines or refractory to treatment can be benchmarked for their drug metabolism function and innate reserve. Therapy can be directed to drugs whose primary metabolic pathway is functional, while avoiding drugs with the most risk, whose primary metabolic pathways are null, poor, deficient or ultra-rapid.

Presentation:
"Science of Personalized Health with DNA-Guided Medical Management Systems"

Genomas Publications:
"Increased carrier prevalance of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital"

"High Carrier Prevalence" of Deficient and Null Alleles of CYP2 Genes in a Major USA Hospital : Implications for Personalized Drug Safety."

"Somatic Complications of Psychotropic Medications in a Patient with Multiple CYP2 Drug Metabolism Deficiencies"

"Physiogenomic Analysis of CYP450 Drug Metabolism Correlates Dyslipidemia with Pharmacogenetic Functional Status in Psychiatric Patients." Biomarkers in Medicine

"Novel Drug Metabolism Indices for Pharmacogenetic Functional Status Based on Combinatory Genotyping of CYP2C9, CYP2C19 and CYP2D6 Genes." Biomarkers in Medicine

"Guidance of Pharmacotherapy in a Complex Psychiatric Case by CYP450 DNA Typing." Journal of the American Academy of Nurse Practitioners

Information Brochures:
HILOmet DNA Typing System Trifold

HILOmet Brochure



Copyright © 2017 Genomas, Inc. All Rights Reserved.